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Abstract 
Background:  Nodding  syndrome  (NS)  is  a  seemingly progressive epilepsy disorder of   unknown underlying cause. 
We investigated association of  pyridoxal-phosphate serum levels and occurrence of   anti-neuronal  antibodies  against  N-
methyl-D-aspartate  (NMDA)  receptor  and  voltage  gated potassium channel (VGKC) complex in NS patients. 
Methods:  Sera of  a Tanzanian cohort of  epilepsy and NS patients and community controls were tested  for  the  pres-
ence  of   anti-NMDA-receptor  and  anti-VGKC  complex  antibodies  by  indirect immunofluorescence assay. Furthermore 
pyridoxal-phosphate levels were measured. 
Results:  Auto-antibodies  against  NMDA  receptor  or  VGKC  (LG1  or  Caspr2)  complex  were  not detected in sera of  
patients suffering from NS (n=6), NS plus other seizure types (n=16), primary generalized  epilepsy  (n=1)  and  commu-
nity  controls  without  epilepsy  (n=7).  Median  Pyridoxal-phosphate levels in patients with NS compared to patients with 
primary generalized seizures and community controls were not significantly different. However, these median pyridoxal-
phosphate levels are significantly lower compared to the range considered normal in Europeans. 
Conclusions: In this pilot study NS was not associated with serum anti-NMDA receptor or anti-VGKC complex antibodies 
and no association to pyridoxal-phosphate serum levels was found.  
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Introduction 
Nodding syndrome (NS) is a distinctive epilepsy disor-
der leading to a progressive encephalopthy with severe 
cognitive  decline  and  neurological  impairment  in 
some  children  with  appearance in geographically lo-
calized areas in South Sudan [1–3], southern Tanzania 
[4 7], and northern Uganda [8-11]. Nodding attacks are 
clinically characterized by loss of  neck muscle tone and 
consequently 
vertical  head  nodding,  often  accompanied  by other
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types  of   epileptic  seizures  and  impaired conscious-
ness [2,5,6,9,1214].  NS  is  variably  associated  with 
growth  retardation,  malnutrition, delayed  sexual  de-
velopment  and  cognitive  impairment  [2,3,5,9,12]. 
The cause  of   this  epilepsy disorder is unknown, as-
sociation with parasitic infection such as Onchocerca 
volvulus and Mansonella perstans as well as toxic expo-
sures and nutritional deficiencies, especially pyridoxine 
(vitamin B6) have been proposed [2,5,9,1518]. Mag-
netic resonance imaging (MRI) showed brain atrophy 
in some patients in a study by Sejvar et al.[9], whereas 
gliotic changes and hippocampal pathologies were de-
scribed by Winkler et al. [5,17]. The same study showed 
familial clustering and interictal epileptic activity such as 
intermittent generalized slowing and sharp wave activ-
ity suggesting an absence type epileptic nature of  dis-
ease [5,6], whereas EEG changes during the actual head 
nodding attack were classified as atonic seizures [9].  
Clinical  signs  and  symptoms  of   NS  include  im-
paired  consciousness,  tremors,  drooling  and inconti-
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nence of  urine as well as psychiatric disturbances [2,5,9]. 
This clinical picture may also be seen in  autoimmune 
encephalopathies  [19]  and  it  was  therefore  tempt-
ing  to  speculate  thatNS is associated with antibodies 
to cellsurface  proteins  expressed  in  neurons  [20]. 
Therefore,we investigated sera of  a Tanzanian epilepsy 
cohort including NS patients and community controls 
originally  collected  for  studies  described  in  [21]  - for 
the  presence  of   anti-NMDA  (N-methylDaspartate) 
receptor and antiVGKC (voltage gated potassium chan-
nel) complex antibodies as a pilot study.  Furthermore 
we measured pyridoxalphosphate  serum  levels  in  a 
set  of   patients  and community controls of  the same 
Tanzanian cohort.  
 
Methods:  
The original study was conducted in The Mahenge Epi-
lepsy Clinic, Mahenge, Tanzania. A detailed description 
of  the  study  population  has  been  described  else-
where  [21].  The study  had  been approved by the Eth-
ics Committee of  the Muhimbili University College of  
Health Sciences,Dar es Salaam. Informed consent was 
obtained from all participants.  
 
In  brief,  clinical  characteristics,  skin  snips,  blood 
samples  were  collected  in  patients  regularly attending 
The Mahenge Epilepsy Clinic. Four different patient 
groups were defined: people with epilepsy with and 
without onchocerciasis and people not suffering from 
epilepsy with and without detection of  onchocercia-
sis. People with epilepsy were further classified in sub-
groups of  either primary generalized seizures, focal sei-
zures, NS only or NS and occurrence of  other epileptic 
seizure types [21]. According to current nomenclature 
study groups of  patients with NS or NS and other sei-
zures  types  correspond  to  NS  and  NS  plus  [5,14]. 
As control groups  patients with  primary generalized 
epilepsy  (PGE)  without  NS  and  community  con-
trols  (CC)  without  history  of   epileptic disorders or 
NS were enrolled according to the study protocol [21]. 
In all patients and community controls polymerase 
chain reaction (PCR) for Onchocerca volvulus has been 
performed on skin snips as described earlier in [21].  
All  samples  (collected  in  2005)  were  transferred  to 
the  Neurological  Laboratory,  Department  of  Neu-
rology, Innsbruck Medical University, Austria. Samples 
were defrosted once for detection of  IgG4 antibod-
ies against Onchocerca volvulus [21], and were then 
stored at 20°C without further freezethaw cycles. For 
the current study, 30 randomly selected samples with 
sufficient amount of  available serum  of   patients  with 
NS,  NS  plus,  PGE  only  or  CC  were  thawed  once 
for  detection  of   either pyridoxalphosphate or of  an-
tineuronal antibodies. Autoantibodies against NMDA 
receptors and VGKC complex, particularly LGI1 and 
Caspr2, were detected by a commercially available cell-
based indirect immunofluorescence assay according to 
the manufacturer’s  instructions (www.euroimmun.de/
index.php?id=29&L=1). The assay uses transfected im-
mobilized HEK293 cells which  are  incubated  with 
test  sera  at  a  dilution  of   1:10.  Secondary antihuman 
fluorescein isothiocyanate labeled IgG antibodies are 
used for detection of  specific autoantibodies. To con-
trol for background  activity  nontransfected  HEK293 
cells were  used  and  in  each  run  a  positive  and  a 
negative control serum was included. Evaluation was 
done in a blinded fashion at the Neurological Labora-
tory, Department of  Neurology, Innsbruck Medical 
University, Austria.  
Pyridoxine was measured as pyridoxal-phosphate, the 
active  pyridoxal-phosphate  metabolite. 
Pyridoxalphosphate  levels  were  measured  in  patients 
and  community  control  serum  samples according  to 
routinely  performed  procedures  in  the  central  labo-
ratory  of   the  InnsbruckMedical University, Austria. 
An IVDCE certified HPLCFLD assay  (Chromsystems, 
Munich,  Germany)  with external calibration and an in-
ternal standard was used. The assay was linear between 
1.0 and 260.0 µg/l, an inter-day variability of  < 6.0% 
was observed.  
Pyridoxalphosphate serum levels are given in median 
and range values and were compared within study 
groups by 1way ANOVA. Statistical significance was 
defined as a 2sided P value < 0.05. 
 
Results:  
Patients’ demographic data are listed in Table 1. Au-
toantibodies against NMDA receptors or VGKC com-
plex (LG1 or Caspr2) were not detected in serum of  
patients suffering from NS (n= 6), NS plus (n= 16) or 
PGE (n=1). In the serum of  CC (n= 7) one sample 
was found positive for antiVGKC Caspr2 complex an-
tibodies. Skin snips tested positive for onchocerciasis in 
69% of  NS, 81% of  NS plus, 55% of  PGE patients and 
100% of  CC (Table 1).  
Table 1 
Numbers, sex and median age (range) of  patients in dif-
ferent study groups of  patients with nodding syndrome 
(NS),  nodding  syndrome  and  other  epileptic  disor-
ders  (NS  plus),  primary  generalized epilepsy (PGE) 
and community controls (CC). 
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Table 1 Demographics      
Pyridoxine      
  n female Median Age (Range) Onchocerciasis (positive Skin snip)
NS 10 5 14,5 (12-18) 7
PGE 10 4 14,5 (12-18) 5
CC 10 4 29,5 (22-31) 10
      
NMDA-Receptor and VGKC Complex Antibodies 
 
  n female Median Age (Range) Onchocerciasis (positive Skin snip)
NS  6 5 15 (13-65) 4
NS plus 16 7 17 (12-30) 13
PGE 1 0 16 1
CC 7 2 50 (26-65) 7
Median Pyridoxal-phosphate serum levels in patients 
with NS (2,11 µg/L, range 1,0 –4,86 µg/L,  n=10) com-
pared to PGE patients (1,96 µg/L, range 1,0  6,18 µg/L, 
n=10) and CC (2,76 µg/L, range 1,07 6,33 µg/L, n=10) 
yielded no statistically significant difference (Figure 1). 
However, median pyridoxalphosphate  levels  are  sig-
nificantly  lower  compared  to  the  range  considered 
normal  in Europeans (6-18µg/L). 
 Figure 1 
Serum pyridoxalphosphate levels of  nodding syndrome (NS) patients, pimary generalized epilepsy patients (PGE)
and community controls (CC). Boxes and whiskers, median and interquartile range.  P not significant. 
 
Discussion: 
Serum antiNMDAreceptor or antiVGKCcomplex an-
tibodies were not detected in NS, NS plus or PGE pa-
tients. Surprisingly we found one positive sample for 
antiVGKC Caspr2 complex antibodies in a community 
control group without epilepsy or NS in his medical 
history. Since this specific subject showed no signs or 
symptoms of  any epilepsy disorder at the time of  tak-
ing the serum sample and was  not  followed  up,  this 
finding  cannot  be  related  to  any  neurologic  disorder 
of   later  onset.  
Recently, Winkler et al. published a followup Study on 
NS patients from the same cohort; however community 
controls have not been re-examined [6]. 
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MRI changes, EEG and clinical findings are associated 
with signs and symptoms of  a progressive epileptic en-
cephalopathy in some of  the patients including impaired 
consciousness, tremors, drooling and incontinence 
of  urine as well as psychiatric disturbances [2,5,9,17]. 
This clinical picture may also be seen in autoimmune 
encephalopathies [19] and it was therefore tempting to 
speculate that auto immune antibodies such as antineu-
ronal receptor antibodies might  be  found  circulating 
in  the peripheral blood of  NS or NS plus patients [20]. 
However, this is the first scientificreport to describe 
that anti-neuronal antibodies against NMDA-receptors 
or the VGKC-complex have not been found in NS or 
NS plus patients.  
Low pyridoxalphosphate levels or other nutritional fac-
tors as well as possible exposures to toxinsare hypoth-
esized causes for NS [15,18].  In  the  present  study 
we  measured  Vitamin  B6  levels  of   NS patients, 
and PGE patients and community controls. Levels did 
not differ significantly between these three groups. 
However, when compared to the range of  pyridoxal-
phosphate serum levels considered normal in Europe-
ans, levels were overall significantly lower. Results of  
low pyridoxalphosphate serum levels are consistent 
with findings from others described in literature [18]. 
This might be explained by different food habits and 
availability of  nutrition rich in vitamin B6 or by a lower 
reference range for this population.  In a publication 
by Spencer et al.  environmental, nutritional  and  in-
fectious  factors  in  NS  were  described  in  detail. 
Spencer et al.  discussed  that ingestion  of   food  con-
taminated  by  Penicillium  fungi,  with  its metabolites 
acting as pyridoxine antimetabolites [22], may account 
for low pyridoxal-phosphate levels [16]. 
The current study has some important  limitations. 
First,  our  sample  size  is  small;  second,other neuro-
nal autoimmune antibodies such as antiglutamate  re-
ceptor  antibodies  have  not  been investigated. Third, 
samples were stored for approximately 7 years before 
analysis. Since storage temperature was constant (20°C) 
and freezethaw cycles were avoided, degradation of  
sampledproteins was likely to have been negligible.  
Conclusion
In this pilot study NS and NS plus is not associated 
with antineuronal antibodies against  NMDA receptors 
or VGKC complex  circulating in the serum and it  does 
not seem  to be  associatedwith decreased pyridoxal-
phosphate serum levels. Therefore, further studies are 
essential to elucidate the pathomechanism of  this mys-
terious epileptic encephalopathy affecting endemically 
young people in selected parts of  Eastern Africa.  
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